9-month treatment for drug-resistant tuberculosis
Part of Infections clinical trials.
This study looks at how well a 9-month treatment plan works for people with multidrug-resistant tuberculosis (TB) that is sensitive to a class of drugs called fluoroquinolones. The treatment uses a combination of medicines to fight the infection, and the study will check its effectiveness and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with multidrug-resistant pulmonary tuberculosis.
- Your TB is sensitive to fluoroquinolones (a type of antibiotic).
- You have been prescribed the MDR-END regimen by your doctor according to Korean TB guidelines.
- You are not allergic to any of the study drugs: delamanid, linezolid, levofloxacin, or pyrazinamide.
- You are not pregnant, breastfeeding, or (if you could become pregnant) willing to use contraception during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study tests whether using a detailed sputum test to guide treatment for drug-resistant tuberculosis (TB) leads to better outcomes. Participants' treatment is tailored based on the specific drug resistance found, which may help them recover faster and reduce side effects.
This study tests a shorter six-month treatment for tuberculosis that is resistant to rifampicin, a common antibiotic. The goal is to make treatment easier and possibly safer while still being effective.
This study tests a 6-month treatment with four oral medicines (bedaquiline, delamanid, linezolid, and levofloxacin) for people whose TB is resistant to rifampin. The goal is to see if this all-pill combination is safe and effective in treating this difficult type of TB.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This study tests a shorter treatment for drug-resistant tuberculosis (TB) using a medicine called pretomanid. It aims to see if a shorter course of treatment can effectively cure TB that doesn't respond to a standard drug called rifampicin, reducing treatment time for patients.
Hear when a new Tuberculosis, Multidrug-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.